A novel and multifunctional biomarker for cancer
A German research team has demonstrated the link between Thrombospondin Type-1 Domain containing 7A Protein and various cancer types and presents a new way to use this tumor specific to improve cancer treatment efficiency by early diagnosis. Sought are industrial or institutional partners involved in the development and/or production of cancer biomarkers, cancer diagnosis/therapy, and research of cancer treatment for licensing, transfer of rights, knowledge transfer, or R&D cooperation.
Sought are industrial or institutional partners involved in the development and/or production of cancer biomarkers, cancer diagnosis and therapy, research of cancer treatment, Membranous Nephropathy, or in personalized medicine. Partners are sought for licensing, transfer of rights (pending patent), or knowledge transfer. The innovation could be tested and refined in commercially relevant projects and R&D cooperation.
The timely medical diagnosis of cancer requires biomarkers which are specific for the different cancer types. A German research group has revealed a direct link between specific tumor entities and the expression level of Thrombospondin Type-1 Domain containing 7A protein (THSD7A), which can be utilized as a new tumor antigen to increase the predictive value of in-vitro diagnostic and prognostic detection methods for cancer, leading to an optimized early diagnosis and treatment decision. Immunohistochemistry tests using tissue microarrays were performed on more than 70 tumor entities (including 20.000 tissue spots) and have demonstrated the association between the THSD7A marker and the described tumor entities, e.g. for breast, prostate, renal, and colorectal cancer. Furthermore, THSD7A antibodies are measurable in whole blood, serum, or plasma. This combination makes it a powerful screening tool for tumor identification. For example, in case of the renal disorder Membranous Nephropathy (MN), a concomitant malignancy could be indicated by the presence of THSD7A antibodies. Additionally, the innovation offers the possibility to treat THSD7A expressing cancer cells selectively with cytotoxic compounds linked to anti-THSD7A antibodies to optimize site directed drug application and minimize therapeutic side effects. Due to the strong relation to several tumor entities, THSD7A can be considered a robust and multifunctional biomarker making it a helpful tool for personalized medicine in cancer treatment, which shall directly improve patient care through early diagnosis of the disease and better adjustment of therapeutic measures. Partners could be enterprises or institutions involved in the development and/or production of cancer biomarkers, cancer diagnosis and therapy, research in cancer treatment, Membranous Nephropathy, or in personalized medicine. They could benefit from a transfer of rights of the existing IP (patent pending), licensing, knowledge transfer, or R&D collaborations to test and refine the technology in commercially relevant projects.
Advantages and innovations
The advantages of the invention for tumor screening lies in the combination of easy detection of THSD7A antibodies in serum, plasma, or (whole) blood, and its expression in different relevant neoplasias, e.g. breast, prostate, renal, or colorectal cancer.
Under development/lab tested
Intellectual Property Rights (IPR)
Patent(s) applied for but not yet granted
Register your interest
How it works
- Tell us about yourself
- We’ll discuss with you
- We put the right partners in touch
EEN help you find the right partner, rather than you going it alone.
Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.
These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.
Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.
First we need to check you’re human.
Thank you for verifying your email. We have sent you a confirmation email containing a 6 digit verification code to unlock the form below